Variantyx Revenue and Competitors

Boston, MA USA

Location

$80.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Variantyx's estimated annual revenue is currently $35.5M per year.(i)
  • Variantyx's estimated revenue per employee is $193,750
  • Variantyx's total funding is $80.5M.

Employee Data

  • Variantyx has 183 Employees.(i)
  • Variantyx grew their employee count by -30% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

Genomic Unity® testing uses a single method for detection of multiple types of variants to provide one, unified clinical report. PCR-free whole genome sequencing is paired with in-silico analysis to identify small sequence changes, large structural variants, mitochondrial variants and tandem repeat expansions within a single sample. A complete analysis can be ordered directly, or a more targeted analysis can be selected followed by reflexing up to the complete analysis in case no initial results are identified. Learn more at www.variantyx.com/diagnostic-testing/.

keywords:N/A

$80.5M

Total Funding

183

Number of Employees

$35.5M

Revenue (est)

-30%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Variantyx News

2021-11-22 - Robert Bosch Venture Capital Invests Approx. $26M in Variantyx

Robert Bosch Venture Capital GmbH, the corporate venture capital company of the Bosch Group, completed an investment in Variantyx Inc., a Framingham, MA-based provider of advanced diagnostics and personalized treatment recommendations for oncology patients’ based on their unique genetic makeup. ...

2021-03-25 - Why Families Need the Closure Whole Genome Sequencing Provides

Haim Neerman, CEO of Variantyx. For medical practitioners expertly trained in the scientific methods of discovery, having a young patient with serious health complications from an undiagnosed condition is about as somber and frustrating as it gets. These feelings are only magnified for parents ...

2021-03-15 - Variantyx Secures $20M in Funding for Whole Genome Sequencing Methodology, Advanced Testing Method that Diagnoses Genetic Disorders

BOSTON--(BUSINESS WIRE)--Mar 15, 2021-- Variantyx, a leader in high complexity hereditary disease testing, today announced that they secured $20M in funding for their Whole Genome Sequencing (WGS)-based testing methodology, an advanced genetic testing method currently used to diagnose rare inhe ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$55.7M2004%N/A
#2
$31.9M200N/AN/A
#3
$65.4M2058%N/A
#4
$32.4M209-8%N/A
#5
$33.9M220-1%N/A